AKT inhibitor AKTi-1/2 (10 mM; cat. no. SF2784) was purchased from Beyotime Institute of Biotechnology. The Cell Counting Kit-8 (CCK-8) was purchased from Shanghai Yeasen Biotechnology Co., Ltd. The Annexin V apoptosis kit (cat. no. LHK601-020) was purchased from Beijing Jiamei Nuno Biotechnology Co., Ltd.
Primary rabbit anti-human AKT (cat. no. 4691), phosphorylated (p-)AKT (S473) (cat. no. 4060), p21 (cat. no. 2947), CDK2 (cat. no. 2546), Cyclin E1 (cat. no. 20808), GSK3α (cat. no. 4337), Mcl-1 (cat. no. 94296), cleaved caspase-9 (cat. no. 9508), and GAPDH (cat. no. 5174) antibodies and secondary antibodies were purchased from Cell Signaling Technology, Inc. Secondary antibodies included the HRP-conjugated anti-rabbit antibody (cat. no. 7074) and HRP-conjugated anti-mouse antibody (cat. no. 7076). All primary antibodies were diluted at a ratio of 1:1,000, whilst all secondary antibodies were diluted at a ratio of 1:2,000 for use in the study.